IRD Opus Genetics trades modestly higher post Q4 2025 earnings despite wider than expected per share losses CVE Cenovus posts 281 percent Q4 2025 EPS beat even as shares dip 06 percent in todays trading COEPW Coeptis Warr leadership prioritizes oncology pipeline advancement in its latest quarterly earnings update